Infliximab treatment in a patient with rheumatoid arthritis on hemodialysis

We describe a 60-year-old woman with active rheumatoid arthritis (RA) and endstage renal disease secondary to hypertensive nephrosclerosis undergoing hemodialysis. She had tried multiple antirheumatic medications; however, their usefulness was limited due to toxic side effects or lack of efficacy. S...

Full description

Saved in:
Bibliographic Details
Published inJournal of rheumatology Vol. 29; no. 3; p. 636
Main Authors Singh, Ranju, Cuchacovich, Raquel, Huang, Wenqun, Espinoza, Luis R
Format Journal Article
LanguageEnglish
Published Canada 01.03.2002
Subjects
Antibodies, Monoclonal - administration & dosage
Antirheumatic Agents - administration & dosage
Arthritis, Rheumatoid - complications
Arthritis, Rheumatoid - therapy
Female
Humans
Infliximab
Kidney Failure, Chronic - complications
Kidney Failure, Chronic - therapy
Middle Aged
Renal Dialysis
Online AccessGet more information

Cover

More Information
Summary:We describe a 60-year-old woman with active rheumatoid arthritis (RA) and endstage renal disease secondary to hypertensive nephrosclerosis undergoing hemodialysis. She had tried multiple antirheumatic medications; however, their usefulness was limited due to toxic side effects or lack of efficacy. She was then treated with chimeric antitumor necrosis factor monoclonal antibody (infliximab), which resulted in immediate improvement in clinical and laboratory measures. After about 2 years of therapy, no side effects have been observed. This report expands the spectrum of infliximab to include RA patients with renal insufficiency.
ISSN:0315-162X